Long-term prognostic importance of high levels of sST2 in patient with AMI : a meta-analysis
AJTR Copyright © 2024..
OBJECTIVE: This meta-study aimed to assess the connection between soluble suppression of tumorigenicity 2 (sST2) and extended clinical outcomes in individuals diagnosed with acute myocardial infarction (AMI).
METHODS: We systematically collected pertinent literature from PubMed, Embase and Web of Science. The primary effect measures employed in this research were the hazard ratio and 95% confidence intervals. The quality and publication bias of included studies were evaluated. Subgroup analysis was conducted to explore the diversity in study outcomes.
RESULTS: This comprehensive meta-analysis ultimately encompassed thirteen studies, involving a total of 11,571 patients. Elevated levels of sST2 were identified as an adverse prognostic indicator, demonstrating a substantial association not only with overall mortality (combined HR 2.4, 95% CI 1.6-3.5, P < 0.01) but also with major adverse cardiovascular events (MACEs) (HR 2.5, 95% CI 1.5-4.2, P < 0.01). Subgroup analyses revealed that increased sST2 levels were linked to higher rates of all-cause mortality and MACEs in patients with ST-segment elevation myocardial infarction (STEMI), non-ST-segment elevation myocardial infarction (NSTEMI), and other unselected subcategories of AMI.
CONCLUSION: Increased sST2 could predict the long-term prognosis in patients suffering from AMI.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:16 |
|---|---|
| Enthalten in: |
American journal of translational research - 16(2024), 1 vom: 24., Seite 1-11 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ji, Haigang [VerfasserIn] |
|---|
| Themen: |
Acute myocardial infarction (AMI) |
|---|
| Anmerkungen: |
Date Revised 26.04.2024 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM36811760X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36811760X | ||
| 003 | DE-627 | ||
| 005 | 20240426233643.0 | ||
| 007 | tu | ||
| 008 | 240207s2024 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n1388.xml |
| 035 | |a (DE-627)NLM36811760X | ||
| 035 | |a (NLM)38322566 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ji, Haigang |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Long-term prognostic importance of high levels of sST2 in patient with AMI |b a meta-analysis |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Revised 26.04.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a AJTR Copyright © 2024. | ||
| 520 | |a OBJECTIVE: This meta-study aimed to assess the connection between soluble suppression of tumorigenicity 2 (sST2) and extended clinical outcomes in individuals diagnosed with acute myocardial infarction (AMI) | ||
| 520 | |a METHODS: We systematically collected pertinent literature from PubMed, Embase and Web of Science. The primary effect measures employed in this research were the hazard ratio and 95% confidence intervals. The quality and publication bias of included studies were evaluated. Subgroup analysis was conducted to explore the diversity in study outcomes | ||
| 520 | |a RESULTS: This comprehensive meta-analysis ultimately encompassed thirteen studies, involving a total of 11,571 patients. Elevated levels of sST2 were identified as an adverse prognostic indicator, demonstrating a substantial association not only with overall mortality (combined HR 2.4, 95% CI 1.6-3.5, P < 0.01) but also with major adverse cardiovascular events (MACEs) (HR 2.5, 95% CI 1.5-4.2, P < 0.01). Subgroup analyses revealed that increased sST2 levels were linked to higher rates of all-cause mortality and MACEs in patients with ST-segment elevation myocardial infarction (STEMI), non-ST-segment elevation myocardial infarction (NSTEMI), and other unselected subcategories of AMI | ||
| 520 | |a CONCLUSION: Increased sST2 could predict the long-term prognosis in patients suffering from AMI | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Soluble suppression of tumorigenicity 2 (sST2) | |
| 650 | 4 | |a acute myocardial infarction (AMI) | |
| 650 | 4 | |a major adverse cardiovascular events (MACEs) | |
| 650 | 4 | |a myocardial infarction (MI) | |
| 650 | 4 | |a prognosis | |
| 700 | 1 | |a Yuan, Ling |e verfasserin |4 aut | |
| 700 | 1 | |a Jiang, Wenbo |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Jing |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t American journal of translational research |d 2009 |g 16(2024), 1 vom: 24., Seite 1-11 |w (DE-627)NLM193229463 |x 1943-8141 |7 nnns |
| 773 | 1 | 8 | |g volume:16 |g year:2024 |g number:1 |g day:24 |g pages:1-11 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 16 |j 2024 |e 1 |b 24 |h 1-11 | ||